MA Jun, LU Ze-sheng. Assessment of the Phase Ⅲ Randomized Multicenter Study of A Humanized Anti-CD33 Monoclonal Antibody,Lintuzumab, in Combination with Chemotherapy, Versus Chemotherapy alone in Patients with Refractory or First Relapsed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2007, 7(4): 213-215. DOI: 10.3969/j.issn.1671-5144.2007.04.007
|
Citation:
|
MA Jun, LU Ze-sheng. Assessment of the Phase Ⅲ Randomized Multicenter Study of A Humanized Anti-CD33 Monoclonal Antibody,Lintuzumab, in Combination with Chemotherapy, Versus Chemotherapy alone in Patients with Refractory or First Relapsed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2007, 7(4): 213-215. DOI: 10.3969/j.issn.1671-5144.2007.04.007
|
MA Jun, LU Ze-sheng. Assessment of the Phase Ⅲ Randomized Multicenter Study of A Humanized Anti-CD33 Monoclonal Antibody,Lintuzumab, in Combination with Chemotherapy, Versus Chemotherapy alone in Patients with Refractory or First Relapsed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2007, 7(4): 213-215. DOI: 10.3969/j.issn.1671-5144.2007.04.007
|
Citation:
|
MA Jun, LU Ze-sheng. Assessment of the Phase Ⅲ Randomized Multicenter Study of A Humanized Anti-CD33 Monoclonal Antibody,Lintuzumab, in Combination with Chemotherapy, Versus Chemotherapy alone in Patients with Refractory or First Relapsed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2007, 7(4): 213-215. DOI: 10.3969/j.issn.1671-5144.2007.04.007
|
DownLoad: